Abstract Purpose: Vascular endothelial growth factor (VEGF)-A is an important mediator of angiogenesis in almost all solid tumors.The aim of this study was to evaluate the effect of VEGF-A expression on tumor growth, perfusion, and chemotherapeutic efficacy in orthotopic 9L gliosarcomas. Experimental Design: Stable 9L cell lines underexpressing and overexpressing VEGF-A were generated. Anatomic, susceptibility contrast, and continuous arterial spin-labeling magnetic resonance imaging were used to quantify the volume, blood volume, and blood flow of tumors orthotopically grown from these and wild-type 9L cells. Histologic, immunohistochemical, and quantitative reverse transcription-PCR analyses were also done on excised tumors. Finally, the effects of carmustine chemotherapy were also evaluated. Results: Orthotopic tumors underexpressingVEGF-A had slower growth rates (increased median survival), greater blood flow, vessel density, andVEGF-D expression, but no statistical difference in blood volume and chemotherapeutic sensitivity, compared with tumors with wild-type levels of VEGF-A. Tumors overexpressing VEGF-A had faster growth rates, greater blood volume, vessel density, and blood flow but no statistical difference inVEGF-D expression and chemotherapeutic sensitivity compared with wild-typeVEGF-A-expressing tumors. Conclusion: Blood volume and blood flow are independent and different biomarkers of tumor perfusion.Therefore, both should be measured when characterizing the efficacy of antiangiogenic therapies. Underexpression of VEGF-A does not result in complete inhibition of angiogenesis. Moreover, these tumors have a different perfusion phenotype, suggesting that angiogenesis is mediated by an alternative pathway. The results indicate that VEGF-D is a plausible alternative mediator of this angiogenesis.
Since Folkman's seminal report (1) on the therapeutic implications of tumor angiogenesis, antiangiogenic therapies have been of immense interest to cancer researchers and pharmaceutical companies. Furthermore, because antiangiogenic inhibitors are being evaluated in clinical trials for treatment of malignant brain tumors (2) , it has become necessary to develop validated imaging biomarkers for investigating the effect of antiangiogenic therapies on tumor physiology (3 -7) . It has been postulated that antiangiogenic treatments may modulate tumor blood flow, tumor blood volume, and oxygenation and, therefore, may synergize with radiation and chemotherapy (7) .
The main aim of this study was to evaluate magnetic resonance imaging (MRI) biomarkers of blood flow and blood volume to identify differences in three variants of the orthotopic 9L brain tumor model that had different angiogenic potential. Modulation of tumor angiogenesis was achieved by underexpressing (VEGF À ) and overexpressing (VEGF + ) vascular endothelial growth factor (VEGF)-A with respect to wild-type 9L (VEGF 0 ) expression levels. A key mediator of both normal and pathologic angiogenesis, VEGF-A has been implicated in tumor development (8) , including rodent (9) and human malignant gliomas (2, 10, 11) , through its ability to stimulate angiogenesis by binding to a family of VEGF receptors. Recently, several antiangiogenic tumor therapies have been developed for blocking VEGF-A or its receptors (2) . In the current study, the effect of modulating VEGF-A expression levels on MRI measurements of tumor blood flow and blood volume, tumor growth rates, animal survival, tumor histopathology, and chemotherapeutic sensitivity were investigated.
Materials and Methods
Cloning of VEGF-A. Total cellular RNA was purified from 9L gliosarcoma cells using the RNeasy mini kit (Qiagen, Valencia, CA). Full-length rat VEGF-A was cloned from rat 9L gliosarcoma cDNA using primers (5V -GCTCTAGAGTCGACGCAATCATGAACTTTCTGCT-CTCTTGG-3V , 5V -GCTCTAGAGTCGACTCACCGCCTTGGCTTGTCAC-3V ) based on the rat (glioma derived) VEGF-A cDNA (accession no. NM_031836; ref. 12 ). The PCR product was cloned into plasmid pEF using the XhoI site. Independent clones containing the entire rat VEGF-A cDNA were then sequenced at the University of Michigan DNA Sequencing Core to confirm the appropriate sequence. Due to the use of a single restriction site on both sides of the cDNA, an antisense VEGF-A plasmid was also selected to make the VEGF À tumor cell line.
Cell culture conditions and generation of stable cell lines. The parental VEGF 0 cell line was cultured in DMEM with GlutaMAX (Invitrogen/Life Technologies, Carlsbad, CA), and supplemented with 10% inactivated FCS, penicillin, and streptomycin at 37jC and 5% CO 2 . To generate stable cell lines, the corresponding pEF plasmids (VEGF + or VEGF À ) were transfected into the 9L cell line using FuGene6
(Roche, Basel, Switzerland). After 2 weeks of selection in culture medium containing 400 mg/mL G418 (Invitrogen, Carlsbad, CA), single cell-derived stable lines were obtained and tested for secretion of VEGF-A into the culture medium by SDS-PAGE and Western blotting (see below). To characterize growth rates, the three representative 9L cell lines were plated in multiple parallel 60 mm dishes. Four replicate plates were trypsinized and counted using a Coulter Counter every day for 7 consecutive days. In addition, the sulfur rhodamine-B growth inhibition assay was used to evaluate the sensitivity of each cell line to carmustine [1,3- 
Intracranial tumor implantation. All of the animal work was carried out in the animal facility at the University of Michigan in accordance with federal, local, and institutional guidelines. Intracerebral brain tumors were implanted in male Fischer 344 rats (Charles River Breeding Laboratories, Wilmington, MA) weighing between 125 and 150 g. The rats were anesthetized by an i.p. administration of a xylazine (13 mg/ kg) and ketamine (87 mg/kg) mixture. A small skin incision was made over the right hemisphere. Using a high-speed drill, a 1-mm-diameter burr hole through the skull was created and an inoculum of 1 Â 10 5 VEGF 0 , VEGF + , or VEGF À cells in 5 AL serum-free medium was introduced through a 27-gauge needle to a depth of 3 mm. The rats were allowed to recover after the burr hole was filled with bone wax. Histopathology and immunohistochemistry. The brains of rats bearing orthotopic tumors were removed and fixed in 10% paraformaldehyde following animal euthanasia. Two days later, the fixed tissues were transferred to 70% ethanol (24 hours) and then embedded in paraffin. Formalin-fixed paraffin-embedded specimens were sectioned at a thickness of 5 Am and mounted on poly-L-lysine -coated slides. After deparaffinization and rehydration, sections were stained with H&E for histopathologic evaluation. For immunohistochemical study, slides obtained from formalin-fixed paraffin-embedded brain specimens were subjected to microwave antigen retrieval, done in citrate buffer (pH 6.0), followed by peroxidase blocking (5 minutes), and incubation in proteinase K solution (DAKO, Glostrup, Denmark). To detect von Willebrand factor and VEGF-D, a rabbit polyclonal antibody for von Willebrand factor (DAKO, Glostrup, Denmark) and a monoclonal antibody for VEGF-D (Abcam, Cambridge, MA), diluted (1:200) with PBS containing 2% goat serum, was applied and incubated for 30 minutes. The slides were washed with PBS, treated with a goat anti-rabbit secondary antibody (DAKO EnVision) detection kit, incubated in a 3,3V -diaminobenzidine chromagen (DAKO) solution, and counterstained with hematoxylin. On the anti -von Willebrand factor slides, 10 hotspots per each tumor type were chosen for evaluation of vascular density (number of vessels per Â400 field).
Western blot detection of VEGF proteins. For immunoblot analysis of secreted VEGF-A in cell cultures, all three 9L cell lines were grown to equal density in cell culture medium (see above). After 24 hours, the conditioned medium was removed and filtered through a 0.45 Am filter (Sigma, St. Louis, MO) to remove floating cells and debris, followed by incubation with 50 mL heparin-agarose (Sigma) at 4jC overnight with continuous agitation. Heparin-agarose beads were then spun down and washed thrice with PBS buffer, boiled in reducing Laemmli sample buffer, and resolved by SDS-PAGE. Western analysis was then done using an anti-VEGF-A antibody [Santa Cruz Biotechnology, Inc., Santa Cruz, CA; VEGF(147)]. For immunoblot analysis of VEGF-A and VEGF-D secreted by tumors, orthotopic tumors were harvested from the respective rats, weighed, and frozen immediately in liquid nitrogen. Frozen tumor samples (1 mg tissue per 10 AL) were homogenized using a rotator-stator and 5 mm head (Fischer, Hampton, NH) in radioimmunoprecipitation assay buffer containing protease inhibitors [1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mmol/L NaCl, 50 mmol/L Tris (pH 8.0), 0.2 units/mL aprotinin, 2 Ag/mL leupeptin, 1 Ag/mL pepstatin A, and 2 mmol/L phenylmethylsulfonyl fluoride, 10 AL per 1 mg tissue]. These were then centrifuged at 1,000 Â g for 10 minutes to remove the cell debris. The supernatant was reserved and the concentration of protein estimated using a Bio-Rad detergentcompatible protein assay kit according to the instructions of the manufacturer. Laemmli sample buffer was added to the supernatants to give a final protein concentration of 2 Ag/AL. Western analyses were then done using antibodies for VEGF-A (Abcam) and VEGF-D (Abcam). All the immunoblots were visualized using enhanced chemiluminescence (Pierce, Rockford, IL).
Quantification of mRNA for VEGF-D. From the supernatant of homogenized and centrifuged tumor samples (prepared identically to that used for the Western analysis above), RNA was purified using the RNeasy kit in combination with the RNase-Free DNase Set (Qiagen) to remove cellular DNA. The level of mRNA for VEGF-D was determined by quantitative reverse transcription-PCR done on a DNA Engine Opticon System using a QuantiTect SYBR Green reverse transcription-PCR kit (Qiagen) under the conditions recommended by the manufacturer. Reverse transcription was done (50jC for 30 minutes) using a mixture (20 AL) consisting of 1 AL sample, 10 AL Master mix (Qiagen), 0.2 AL QuantiTect reverse transcription mix, and 1.5 AL (12.5 Amol/L) of each primer specific for the VEGF-D gene sequence (5V -ACAAGATGAGAATCCACTGCCTGG-3V , 5V -CTCCAGGACATGGTGCTT-TACAGA-3V ). This was followed by initial denaturation, enzyme activation (95jC for 15 minutes), and 36 PCR cycles (94jC for 15 seconds, 53jC for 30 seconds, and 72jC for 30 seconds). The levels of mRNA for VEGF-D were normalized against the mRNA levels of h-actin (5V -AGAAGATCTGGCACCACACC-3V , 5V -CTCATCGTACTCCTGGTTGC-3V ) by calculating the difference in cycle threshold (DC T ). The mRNA levels for VEGF-D in the VEGF À and VEGF + tumors were then compared with the mRNA levels for VEGF-D in the VEGF 0 tumors by calculating the difference in DC T (DDC T ). The mRNA levels were then expressed as fold increase (2 ÀDDC T ) as per standard comparative reverse transcrip-
tion-PCR methods (PE Applied Biosystems User Bulletin 2).
Magnetic resonance imaging. A 7 T MRI system (Varian, Inc., Palo Alto, CA) was used to acquire all images. During all MRI procedures, animals were anesthetized with an isoflurane (1.5% in air) and the body temperature was maintained at 37jC using a heated water recirculating pad.
A fast spin echo multislice imaging sequence was used (4-second TR, 60 ms TE eff , 128 Â 128 matrix, 13 Â 1-mm-thick slices, 8 echo train length, and a 3 cm field of view) to image the animals every 2 days. From these images, tumor volumes were determined by drawing tumor regions of interest in each slice using a drawing tool developed with Matlab. Volumes from all slices for an individual animal were summed at each time point and the natural logarithms of these volumes were plotted as a function of time postimplantation to calculate tumor growth rates. In addition, as a measure of tumor latency, the times for tumors to reach a volume of 20 AL (T 20 ) were interpolated from these plots.
A single-coil continuous arterial spin labeling imaging protocol (14) was used to obtain blood flow maps of the orthotopic tumors in vivo. Briefly, continuous arterial spin labeling perfusion and nonperfusion Research.
on April 14, 2017. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from weighted images were acquired using a modified fast spin echo imaging sequence (4-second TR, 15 ms TE eff , 128 Â 128 matrix, 1.5 mm slice thickness, 8 echo train length, and a 3 cm field of view). The perfusion weighting was accomplished with a train of hyperbolic secant inversion pulses to invert the inflowing blood spins preceding the image acquisition. Blood flow images were then calculated on a pixel-bypixel basis from these perfusion images using the following equation:
where F is the blood flow (mL-s/100 g-min); s and s 0 are the perfusion and nonperfusion weighted signal intensities, respectively; a is the labeling efficiency; c is the blood partition coefficient; and T 1 is the effective spin-lattice relaxation time of the water contained within the tissue. Maps of T 1 were calculated from a series of five inversion recovery fast spin echo T 1 weighted images (50 ms to 5-second inversion time, 1-second TR, 15 ms TE eff , 1.5 mm slice thickness, 16 echo train length, 128 Â 64 matrix, and a 3 cm field of view). A nonlinear least-squares fitting algorithm (Levenberg-Marquardt) was used to fit for T 1 on a pixel-by-pixel basis.
Relative cerebral blood volume (rCBV) maps were acquired using a gradient echo T 2 * weighted MRI protocol. Feridex IV (f15 mg Fe/kg; Berlex, Montville, NJ) was administered via the tail vein over a 30-second period. Using a gradient echo MRI sequence, T 2 * weighted images (10 ms TR, 5 ms TE, 1 mm slice thickness, 128 Â 128 matrix, and a 3 cm field of view) were acquired before and after injection (within 5 minutes) through the middle of the tumor. The change in T 2 * relaxivity (DR 2 *) is proportional to blood volume. Therefore, the rCBV maps were calculated on a pixel-by-pixel basis using the following formula:
where DR 2 * av is the mean change in relaxivity of the contralateral brain.
Diffusion MRI was done to obtain maps of tumor apparent diffusion coefficient at baseline and posttherapy using the previously described method (15) . Briefly, a trace diffusion weighted multislice spin echo sequence (with motion compensation and navigator echo) was used to acquire images (3-second TR, 60 ms TE eff , 13 Â 1-mm-thick slices, 128 Â 128 image matrix, and a 30 mm field of view) with two different diffusion weightings (Db value of 1,148 s/mm 2 ). Treatment with BCNU. In an additional set of animals (n = 5 per tumor line), response to BCNU treatment was investigated. When in vivo tumor volumes were between 40 and 60 AL, BCNU (13.3 mg/kg) was administered in 10% ethanol by a single i.p. injection. Diffusion and T 2 weighted MRI was done every other day posttherapy to measure changes in tumor cell density and tumor volume, respectively. Animals were euthanized when discharge appeared around both eyes. Animal survival time was defined as the time from tumor treatment to 1 day after euthanasia.
Statistical analysis. Linear least-squares analysis was used to calculate the tumor growth rates from the semilog plots of tumor volume as a function of time postimplantation. The T 20 values were interpolated from the calculated line of best fit. When results from two groups were compared, a two-tailed Student's t test was used. Both linear least squares and Student's t test were done using Microsoft Excel. A log-rank test was done (Prism, GraphPad Software, Inc., San Diego, CA) to test the statistical significance of differences in animal survival.
Results
In vitro characterization of the 9L cell lines. Two new stable (VEGF À and VEGF + ) 9L brain tumor cell lines were produced. The VEGF-A expression of both these cell lines ( Fig. 1 ) revealed different profiles of VEGF-A expression. The VEGF À cells had no detectable amounts of VEGF-A (Fig. 1,  lane 2) , whereas the VEGF + cells had a significantly higher level of VEGF-A expression (Fig. 1, lane 1) compared with the VEGF 0 cell line (Fig. 1, lane 3) . In addition, the growth rates of the cell lines were measured to determine if changing VEGF-A expression affected the intrinsic growth rate of the 9L tumor cells in culture. As shown in Table 1 , the VEGF À cells had a slightly slower cell growth rate compared with VEGF 0 cells, whereas the VEGF + cells had a slightly faster growth rate. These changes in growth rate also correlated with slight differences in sensitivity to BCNU as determined using the Table 1 ).
Orthotopic growth rate and animal survival. Orthotopic implantation of all three cell lines in Fischer 344 rats resulted in tumor growth in 100% of the animals studied. All three tumor types were clearly visible as hyperintense lesions on anatomic T 2 -weighted MRI scans (Fig. 2A) . The VEGF + tumors were visible f7 days postimplantation, whereas the VEGF 0 and VEGF À tumors were not visible until f10 and 20 days postimplantation, respectively. The VEGF + tumors caused significant amounts of edema in the ipsilateral brain as observed by T 2 hyperintensity, which was not observed in the VEGF 0 or VEGF À tumors. The VEGF À tumors (n = 6) had a significantly (P < 0.001) prolonged latency (Table 1) for tumor development when compared with that of the VEGF 0 tumors (n = 6). In addition, once tumors were established, the VEGF À tumors had a significantly (P = 0.02) slower growth rate ( Fig. 2B ; Table 1 ) and significantly longer survival (P < 0.001; Fig. 2C ; Table 1 ) than VEGF 0 tumors. In contrast, the VEGF + tumors (n = 6) had a significantly (P < 0.001) shorter latency to tumor development (Table 1 ) and a significantly (P = 0.01) shorter median survival than VEGF 0 tumors ( Fig. 2C ; Table 1 ). This shorter median survival time was observed despite the fact that once tumors were established, the doubling time of the VEGF + tumors was not significantly (P = 0.55) shorter than that of the VEGF 0 tumors ( Fig. 2C ; Table 1 ). Histopathology and immunohistochemistry. Pathologic sections from each tumor type were stained with H&E and examined under low and high magnification (Fig. 3A) . All tumors were hypercellular, composed of predominantly spindled cells on a microcystic background. The amount of the cytoplasm was minimal to none in the cells of the VEGF 0 and VEGF À tumors, but quite visible in the VEGF + tumors. Overall, cellularity was highest in the VEGF À tumors due to frequent small rounded nuclei, most of which appeared pyknotic. The nuclei of the VEGF + tumors were larger, with complex chromatin. Varying numbers of multinucleated cells were present in all tumors. The number of mitotic figures ranged from 4 to 11 per high-power field in the VEGF 0 and VEGF + tumors, to 3 to 9 in the VEGF À tumors. The density of blood vessels in the tumors was estimated using anti -von Willebrand factor -stained slides as a marker for endothelial cells (Fig. 3A) . The mean vessel density (FSE) for the VEGF 0 , VEGF À , and VEGF + tumors was 11.8 F 1.2, 16.4 F 1.8, and 73.6 F 9.7 vessels per high-powered microscopic field (Â400), respectively. A Student's t test revealed that the VEGF À tumor vessel density was significantly (P = 0.03) greater than that for the VEGF 0 tumors, but significantly (P < 0.001) less than that for the VEGF + tumors. The anti-VEGF-D immunohistochemistry slides (Fig. 3A) show that only the VEGF À tumors exhibited positive staining for VEGF-D. Although the data are not quantitative, they do show that the VEGF À tumors, in contrast to the VEGF + and VEGF 0 tumors, contained enough VEGF-D to be detected by this method.
Tumor blood volume and blood flow. To determine the effect of VEGF expression on tumor blood flow and blood volume, two independent MRI techniques were used to evaluate these variables. Cerebral blood volume and tumor blood flow maps were acquired once tumors were established (visible on at least three sequential T 2 weighted image slices). This enabled quantification and visualization of blood volume and flow heterogeneity within the tumors. Examples of tumor rCBV and blood flow maps (Fig. 3B) are shown. The VEGF À tumors (Fig. 4A ) had a mean rCBV (2 F 1) that was not significantly (P = 0.85) different than that of the VEGF 0 tumors (2 F 1), whereas the VEGF + tumors had a higher mean rCBV (8 F 3, P < 0.001) compared with both the VEGF À and VEGF 0 tumors. The mean blood flow of these tumors (Fig. 4B ) revealed VEGF + tumors to have the greatest heterogeneity and highest mean blood flow (325 F 24 mL/100 g/min), which was significantly (P < 0.001) greater than the VEGF 0 tumors (43 F 4 mL/100 g/ min). The VEGF À tumors had a mean blood flow (99 F 9 mL/ 100 g/min) that was significantly (P < 0.001) higher than that of the VEGF 0 tumors.
VEGF-A and VEGF-D expression in orthotopic 9L tumors.
To analyze in vivo VEGF-A expression in the 9L tumors, whole tumor lysates (including tumor cells and incorporated stroma within the tumor) were evaluated by Western blot analysis for VEGF-A (Fig. 5) . Confirming the in vitro results (Fig. 1) , the VEGF + tumors contained higher levels (Fig. 5, lane 1) of VEGF-A expression than the VEGF 0 tumors (Fig. 5, lane 3) , whereas the VEGF À tumors, in contrast, showed a significantly lower level (Fig. 5, lane 2) of VEGF-A expression.
Since it has been reported that VEGF-D can also induce angiogenesis through VEGF receptor-2 (16 -18) and is overexpressed in high-grade gliomas (19) , further investigation of VEGF-D expression in these three tumor types was done (Fig. 5) . Figure 5 shows Western blot analyses using an antibody raised to the NH 2 terminus of the mature, fully processed, form of VEGF-D (the mature form is f20 kDa) and that also binds the unprocessed, full-length form (f50 kDa). The results of both Western blot analyses indicate a significantly higher expression level of both VEGF-D forms in VEGF À tumors compared with that of VEGF 0 and VEGF + . In addition, reverse transcription-PCR was done on harvested tumors, revealing To investigate the effect of VEGF-A expression on tumor response to chemotherapy, the three 9L clones were tested for their sensitivity to BCNU both in vitro and in vivo. In vitro sensitivity was tested by comparing the IC 50 of BCNU (Table 1) for each cell line. The IC 50 values of both the VEGF À and VEGF + cell lines were not significantly different from that of the VEGF 0 cell line. For in vivo evaluation, animals were implanted with each 9L cell line and tumors were allowed to develop. To minimize the effect of tumor latency (see Fig. 2 and discussion above), tumors were allowed to reach an equivalent size (f40-60 AL) before BCNU was administered to the animals (13.3 mg/kg). Following treatment with BCNU, the apparent diffusion coefficient increased significantly above baseline within 5 days of therapy (Fig. 6A) . The average apparent diffusion coefficient increase in the VEGF 0 tumors was larger than that observed for the VEGF + and VEGF À tumors; however, this difference did not reach statistical significance (P = 0.071 and 0.075, respectively). The median survival (40 days posttherapy) of animals with VEGF À tumors was significantly (P = 0.02) longer than that for the animals with VEGF 0 (33 days) tumors. Interestingly, this was not significantly (P = 0.7) longer than the survival of animals with VEGF + tumors (36 days; Fig. 6B) . Similarly, the difference in the median survival time between the VEGF 0 and VEGF + groups was not significant (P = 0.35; Fig. 6B ). Tumor volumes obtained from serial MRI scans posttherapy (Fig. 6C ) tumors responded the fastest such that they reached a nadir volume 13.9 days after treatment followed by rapid regrowth.
This was found to be statistically different from the VEGF À tumors (P = 0.02) but not in the VEGF 0 tumors (P = 0.25). The nadir volumes for the VEGF À (20%) and VEGF + (28%) tumors were not statistically different (P = 0.73 and 0.52, respectively) from the VEGF 0 (23%) tumors.
Discussion
Tumors generally depend on angiogenesis for the supply of oxygen and nutrients. Angiogenesis is a complex signaling network between tumor cells, vascular endothelial cells, and the surrounding environment. An attractive target for antiangiogenic therapy is VEGF-A, one of the most abundant and important angiogenic growth factors. Previous work using in vivo glioma models has shown that modulation of VEGF-A expression could alter neoangiogenesis and the growth of tumors after intracerebral implantation (20, 21) . These studies did not use noninvasive imaging and as such were only able to show that early tumor development (f10 days after injection) was decreased by suppressing VEGF-A expression and that animal survival was correspondingly increased. The observation that VEGF À tumors had a significantly longer latency for tumor development followed by increased eventual blood flow is consistent with previous observations (22, 23) . The VEGF-Amediated angiogenesis may play a greater role in early blood vessel recruitment and tumor development while having less of an effect upon the growth of established tumors. The results presented here are also consistent with similar studies (24) wherein intracranially established melanoma tumors overexpressing and underexpressing VEGF-A showed a substantial modulation of tumor growth as well as a decrease in tumor vascularity and blood vessel permeability.
Recent experimental results revealed that when antiangiogenic therapy is used in conjunction with cytotoxic therapies, a synergistic improvement in efficacy is achieved (25) . This led Jain et al. (7) to postulate that the synergy may be due to the ''paradox of antiangiogenic therapy'' referring to observations that antiangiogenic therapies reduce blood vessel growth and permeability while also ''normalizing'' existing blood vessels resulting in a transient increase in blood flow and decrease tumor hypoxia. The increased blood flow allows for improved drug penetration whereas the reduction in tumor hypoxia improves the efficacy of cytotoxic therapies, such as ionizing radiation (25) . To maximize the synergistic effects of combined antiangiogenic and cytotoxic therapies, the development of noninvasive biomarkers of blood flow and tumor oxygenation is extremely important. In this study, we have shown that blood flow as measured by MRI has the potential to be an important biomarker of the normalization of blood vessels during antiangiogenic therapies. The results show that modulation of VEGF-A production resulted in significantly different blood flow properties of orthotopic 9L tumors. Once established, the VEGF À tumors had a higher mean blood flow and blood vessel densities than did the VEGF 0 tumors. Interestingly, the relative blood volume of these tumors was not significantly different from the VEGF 0 tumors. These observations suggest that VEGF-A suppression leads to a more efficient blood vasculature, consistent with the ''normalization'' theory of Jain et al. (7) . It is important to note that the blood flow measurements made using the continuous arterial spin labeling method (14) were completely independent measurements of perfusion from the blood volume maps and different to other contrast enhanced measurements of tumor perfusion (26 -32) .
This study also revealed that restricting the expression of VEGF-A by the tumor cells is not sufficient to block angiogenesis in 9L tumors. The observation that the VEGF À tumors could overcome the VEGF-A deficiency by forming new blood vessels, thereby attaining greater blood flow than parental 9L tumors, suggested the involvement of an alternative pathway or different angiogenic molecule. There are a number of possible explanations for this observation. One possibility is that the VEGF À tumors escaped VEGF-A suppression similar to a previous report (21) . However, Fig. 5 shows that the VEGF À tumors have suppressed VEGF-A expression relative to the VEGF 0 tumors. Another study (33) suggested that stromal production of VEGF-A may contribute significantly to the growth of tumors in rodent tumor models. In that study, maximum antiangiogenic effect occurred when both tumor and host production of VEGF-A was suppressed. This latter fact may explain the higher expression of VEGF-A in VEGF À tumors compared with the expression of VEGF-A in VEGF À cell cultures that was observed in this study. The Western blots and quantitative PCR, however, both identified up-regulation of VEGF-D in the VEGF À tumors compared with that of both the VEGF 0 and VEGF + tumors. These results suggest that VEGF-D is a likely mediator of angiogenesis in these tumors with negligible VEGF-A expression. VEGF-D is a well-known angiogenic (16, 17) and lymphangiogenic (34) growth factor that is most likely regulated by cell-to-cell contact (35) . VEGF-A and VEGF-D are also both highly expressed in glioblastoma (2) . Considering the angiogenic ability of VEGF-D, it is perhaps not surprising to observe that in tumors in which the availability of VEGF-A was restricted, the tumors were subsequently able to up-regulate VEGF-D. In accordance with this theory, current pharmacologic research and recent clinical trials in patients with high-grade glioma have revealed enhanced suppression of angiogenesis and a clinical benefit through the inhibition of all receptors within the VEGF family (36, 37) .
When treated with BCNU, the different 9L tumor types showed different response rates. However, this did not translate into significant differences in apparent diffusion coefficient change and nadir volume although the time to nadir and animal survival were significantly longer for the VEGF À tumor compared with the VEGF 0 tumors. The increase in survival following BCNU treatment of the VEGF À tumors can largely be accounted for by the slower doubling time of the VEGF À tumors and does not support an increase in BCNU sensitivity as the major factor in this prolonged survival. The effect of tumor growth rate on survival following BCNU treatment can also be seen when comparing the survival of animals bearing the different VEGF-A expressing tumors that were treated (Fig. 6B) or not treated (Fig. 2C ). The differences in survival between the groups were similar whether they received treatment or not; however, the overall median survival was increased for each group with BCNU treatment.
In conclusion, altering the expression levels of VEGF-A in the 9L tumor model resulted in significant changes in tumor perfusion. Both the 9L tumor models overexpressing and underexpressing VEGF-A exhibited elevated tumor blood flow. Blood volume was elevated in the overexpressing VEGF-A tumors, but was not significantly altered in underexpressing tumors. In addition, when VEGF-A was inhibited, there was an increased latency period until tumors developed; however, once they were established, they developed a more efficient blood supply than the wild-type tumors. Subsequent analysis showed that the development of these blood vessels may have occurred as a result of VEGF-D up-regulation. These results show the ''adaptive ability'' of tumor cells to antiangiogenic therapy. Not only do tumors have multiple pathways for angiogenic signaling, but they also have the ability to call on these secondary pathways when the primary pathway is inhibited. It should also be noted that for brain tumors the up regulation of VEGF-D and its potential for lymphangiogenesis may not be a concern due to the negligible amount of lymph vessels in the brain for co-option. However, for antiangiogenic treatments targeting only VEGF-A in tumors located where lymphatic vessels can be co-opted, these results raise the possibility of increased lymphatic spread and metastatic potential.
These results show that antiangiogenic treatments may be used effectively in combination with chemotherapy and/or radiotherapy (38) . Therefore, finding the optimal combination, dose, and timing of these therapies for maximizing the synergistic effects poses important challenges for cancer therapy. To confront these challenges, it is becoming clear that imaging biomarkers of antiangiogenic therapeutic efficacy are extremely important. The results of this study show that the clinically translatable MRI blood flow and blood volume maps are independent imaging strategies that can provide complementary and important information with respect to tumor angiogenesis.
